Table 1 Clinical characteristics of the patients with the low-risk group and high-risk group
Patients (n = 83) | Low-risk group, n (%) 51 (61) | High-risk group, n (%) 32 (39) | p-value* |
|---|---|---|---|
Sex, n (%) | |||
Male | 25 (49) | 20 (62) | 0.23 |
Female | 26 (51) | 12 (38) | |
Age, median (range) (years) | 50 (21–73) | 50 (24–66) | 0.68 |
Smoking status, n (%) | |||
Never | 34 (67) | 18 (56) | 0.34 |
Current or past smoker | 17 (33) | 14 (44) | |
Previous malignancy or synchronous tumor, n (%) | |||
Absent | 48 (94) | 27 (52) | 0.25 |
Present | 3 (6) | 5 (48) | |
Clinical presentation, n (%) | |||
Asymptomatic | 16 (31) | 10 (31) | 0.99 |
Symptomatic | 35 (69) | 22 (69) | |
Myasthenia gravis, n (%) | |||
Absent | 43 (84) | 22 (69) | 0.09 |
Present | 8 (16) | 10 (31) | |
LDH, median (range) (U/L) | 180 (113–338) | 179 (89–310) | 0.80 |
ALP, median (range) (U/L) | 68 (29–124) | 67 (31–167) | 0.74 |
CRP, median (range) (mg/L) | 4.1 (0.6–70.7) | 3.5 (0.1–25.8) | 0.67 |
HGB, median (range) (g/dL) | 14 (9–16.6) | 13.6 (9–16.3) | 0.62 |
WBC count, median (range) (×109/L) | 7.7 (3.3–16.8) | 7.3 (3.9–13.9) | 0.97 |
LYMP count, median (range) (×109/L) | 2.1 (0.01–6.1) | 1.8 (0.5–3.8) | 0.10 |
PLT count, median (range) (×109/L) | 258 (121–454) | 233 (122–404) | 0.58 |
Type of treatment, n (%) | |||
Surgery±adjuvant treatment | 44 (86) | 28 (87) | 1.00 |
Definitive chemotherapy±radiotherapy | 7 (14) | 4 (13) | |
Largest dimension of tumor size on CT (mean ± SD) (range) in mm | 66.8± 2.1 (21–160) | 63±2.2 (20–134) | 0.55 |